ACVRL1 and neoplasm: Although several proteins (e.g., ACVRL1, DUSP4, PREX1) showed increased expression in the high-risk group, PD-L1 and p38 MAPK were prioritized for mechanistic validation due to their established roles in tumor-immune interactions (34, 35).